Publications 2017

2017

Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).

Ho PJ, Tay L, Teo J, Marlton P, Grigg A, St Pierre T, Brown G, Badcock CA, Traficante R, Gervasio OL, Bowden DK (2017).

Eur J Haematol. 2017 98(2)97-105

2017

A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.

Ho PJ, Bajel A, Burbury K, Dunlop L, Durrant S, Forsyth C, Perkins A, Ross DM.

2017 Intern Med J. 47(3):262-268.

2017

Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end stage renal disease (ESRD): an open-label, single-arm, phase I study.

CQuach H, White D, Spencer A, Ho PJ, Bhutani D, White M, Inamdar S, Morris C, Ou Y, Gyger M.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1067-1076.

2017

Real-world’ Australian experience of pomalidomide for relapsed and refractory myeloma.

Scott A, Weber N, Tiley C, Taylor K, Taper J, Harrison S, Chan KL, Stark R, Lee C, Morris K, Ho PJ, Dodds A, Ramanathan S, Ramakrishna R, Watson AM, Auguston B, Kwok F, Quach H, Warburton P, Rowlings P, Mollee P (2017).

Leuk Lymphoma 12:1-3.

2017

The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells.

Slavica Vuckovic, Kate Vandyke, David A Rickards, Padraig McCauley Winter, Simon HJ Brown, Todd W Mitchell, Jun Liu, Jun Lu, Philip W Askenase, Elizabeth Yuriev, Ben Capuano, Paul A Ramsland, Geoffrey R Hill, Andrew CW Zannettino, Andrew T Hutchinson.

British Journal of Haematology, 2017;177: 423-440.

2017

Eomesodermin promotes the development of type 1 regulatory T (TR1) cells.

Ping Zhang, Jason S. Lee, Kate H. Gartlan, Iona S. Schuster, Iain Comerford, Antiopi Varelias, Md Ashik Ullah, Slavica Vuckovic, Motoko Koyama, Rachel D. Kuns, Kelly R. Locke, Kirrilee J. Beckett, Stuart D. Olver, Luke D. Samson, Marcela Montes de Oca, Fabian de Labastida Rivera, Andrew D. Clouston, Gabrielle T. Belz Bruce R. Blazar, Kelli P. MacDonald, Shaun R. McColl, Ranjeny Thomas, Christian R. Engwerda, Mariapia A. Degli-Esposti, Axel Kallies, Siok-Keen Tey, Geoffrey R. Hill.

Science Immunology 07 Apr 2017: Vol. 2, Issue 10, eaah7152,DOI: .1126/sciimmunol.aah7152.

2017

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.

Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng WJ, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S, Iskander KS, Dimopoulos MA. Leuk Lymphoma.

2017 Sep 22:1-11. doi: 10.1080/10428194.2017.1376743.

2017

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Horvath N, Lee C, Zannettino A, Brown R, Augustson B, Jaksic W, Gibson J, Kalff A, Johnston A, Trotman J, Kalro A, Grigoriadis G, Ward C, Prince HM.

Intern Med J. 2017 Jan;47(1):35-49. doi: 10.1111/imj.13311.

2017

Unusual case of splenomegaly and pancytopenia in a returned traveler.

Alcheikh A, Lynar S, Brown C, Lee A, Bryant C. Intern Med J.

2017 Nov;47(11):1325-1326. doi: 10.1111/imj.13604.

2017

Tattoo Pigment-Induced Granulomatous Lymphadenopathy Mimicking Lymphoma.

Othman J, Robbins E, Lau EM, Mak C, Bryant C. Ann Intern Med.

2017 Dec 5;167(11):830-831. doi: 10.7326/L17-0424. Epub 2017 Oct 3.

2017

Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.

McCulloch D, Brown C, Iland H.

OncoTargets Ther 2017; 10:1585-1601.

2017

Sensitive monitoring of acute promyelocytic leukemia by PML-RARA DNA Q-PCR.

Kommers IO, Bartley PA, Budgen B, Latham S, Beligaswatte A, Supple SG, Catalano A, Iland HJ, Morley AAM, Ross DM.

Leuk Lymphoma 2017; 58(7):1767-1769.

2017

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.

Mantha S, Goldman DA, Devlin SM, Lee J-W, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM, Appelbaum FR, Larson RA, Stone RM, Powell BL, Geyer S, Laumann K, Rowe JM, Erba HP, Coutre S, Othus M, Park JH, Wiernik PH, Tallman MS.

Blood 2017; 129(13):1763-1767.

2017

Patient Reported Outcomes in Optimizing Myeloma Patients’ Health-Related Quality of Life.

King T, King M, White K.

Seminars in Oncology Nursing (2017)  33:299-315 DOI 10.1016/j.soncn.2017.05.006

2017

A Review of Steroid-Associated Side Effects and Important Considerations in Multiple Myeloma: A Symptom Management Update on behalf of the International Myeloma Foundation Nurse Leadership Board. 

King T, Faiman B. (2017).

Clinical Journal of Oncology2017; 21(2):240-249. DOI:10.1188/17.CJON.240-249

2017

On behalf of the International Myeloma Foundation Nurse Leadership Board. Evidence-Based Recommendations for Renal, Gastrointestinal and Peripheral Nerve-Related Symptoms Management: An Update from the 2008 IMF Nurse Leadership Board Consensus Guidelines for the Care of Patients with Multiple Myeloma. 

B Faiman, Doss, D., Colson K, ManganP, T King, J Tariman, (2017)

Clinical Journal of Oncology Nursing. 21(5supp):19-36